The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

With an upside potential of 32.01%, Embecta Corp. (NASDAQ:EMBC) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts.

On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 while maintaining an Underperform rating on the shares. Following meetings with 34 medtech companies in Las Vegas, the analyst updated multiple healthcare valuation models to reflect what the firm described as a “new reality” for medtech stocks. Bank of America cited concerns surrounding a lack of major product cycles, the Affordable Care Act, and utilization-related uncertainties, inflationary pressures following geopolitical instability, and investor preference shifting toward artificial intelligence and data center investments rather than healthcare equities. The revised target reflects broader sector-wide caution despite Embecta’s established presence in diabetes care solutions.

Earlier, on May 6, Mizuho Financial Group lowered its price target on Embecta Corp. (NASDAQ:EMBC) to $5 from $12 while maintaining a Neutral rating. The adjustment came amid continued pressure across the broader medical technology sector, where analysts remain cautious regarding reimbursement trends, healthcare utilization patterns, and the pace of innovation-driven growth. Despite the lowered valuation targets, Embecta continues to maintain a significant position within the global diabetes care market through its specialized insulin delivery product portfolio.

Founded in 2022 and headquartered in Parsippany, Embecta Corp. (NASDAQ:EMBC) is a global medical technology company focused exclusively on diabetes care solutions. The company specializes in insulin delivery systems, including syringes and pen needles, while also investing in digital health technologies aimed at improving diabetes management and patient outcomes.

While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Heavy Equipment Stocks to Buy as Backlogs Hit Records and 9 Best Natural Gas Stocks to Buy for Transitional Power.

Disclosure: None.  Follow Insider Monkey on Google News.